SCHEMBL7056985

SCHEMBL7056985

CCOC(=O)c1cn(CC)c2ccccc2c1=O

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.69
TDP1 Q9NUW8 1/20 0.67
NR4A2 P43354 1/20 0.62
POLB P06746 1/20 0.55
HPGD P15428 4/20 0.54
KMT2A Q03164 3/20 0.54
MEN1 O00255 2/20 0.54
MAPT P10636 1/20 0.54
THRB P10828 1/20 0.54
CNR1 P21554 1/20 0.54
MAOB P27338 1/20 0.52
TSHR P16473 1/20 0.52
MAPK1 P28482 1/20 0.52
CREBBP Q92793 1/20 0.51
KDM4E B2RXH2 3/20 0.51
ALDH1A1 P00352 3/20 0.51
HSD17B10 Q99714 2/20 0.51
NPC1 O15118 1/20 0.51
HTT P42858 1/20 0.51
RAB9A P51151 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2090257 0.90 NR4A2 (0.76) LMNATDP1NR4A2POLBCNR1
SCHEMBL23914948 0.88 KMT2A (0.60) LMNATDP1POLBKMT2ACNR1
SCHEMBL18833437 0.87 KMT2A (0.69) LMNATDP1NR4A2POLBHPGD
SCHEMBL18833435 0.87 CNR1 (0.68) LMNATDP1CNR1
SCHEMBL15956289 0.87 LMNA (0.70) LMNAALDH1A1P2RX3
SCHEMBL28158748 0.86 NR4A2 (0.62) LMNATDP1NR4A2HPGDTSHR
SCHEMBL18833432 0.86 CNR1 (0.73) CNR1
SCHEMBL30417310 0.85 CNR1 (0.72) CNR1
SCHEMBL18833434 0.85 CNR1 (0.72) CNR1
SCHEMBL15071685 0.84 ALDH1A1 (0.57) LMNATDP1NR4A2HPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022035763-A1 BORON CONTAINING COMPOUNDS AND THEIR USES 5METIS, INC. (US) 2022-02-17 WO disclosed
WO-2020264581-A1 BORON CONTAINING COMPOUNDS AND THEIR USES Boragen, Inc. (US) 2020-12-30 WO disclosed
US-10087144-B2 Agents for use in the treatment of cardiovascular and inflammatory diseases structurally based on 4(1 H)-quinolone UCL BUSINESS PLC (GB) 2018-10-02 US disclosed
EP-3145914-A1 AGENTS FOR USE IN THE TREATMENT OF CARDIOVASCULAR AND INFLAMMATORY DISEASES STRUCTURALLY BASED ON 4(1 H)-QUINOLONE UCL Business PLC (GB) 2017-03-29 EP disclosed
US-20170066722-A1 AGENTS FOR USE IN THE TREATMENT OF CARDIOVASCULAR AND INFLAMMATORY DISEASES STRUCTURALLY BASED ON 4(1 H)-QUINOLONE UCL BUSINESS PLC (GB) 2017-03-09 US disclosed
US-20170066722-A1 AGENTS FOR USE IN THE TREATMENT OF CARDIOVASCULAR AND INFLAMMATORY DISEASES STRUCTURALLY BASED ON 4(1 H)-QUINOLONE UCL BUSINESS PLC (GB) 2017-03-09 US disclosed
US-20170066722-A1 AGENTS FOR USE IN THE TREATMENT OF CARDIOVASCULAR AND INFLAMMATORY DISEASES STRUCTURALLY BASED ON 4(1 H)-QUINOLONE UCL BUSINESS PLC (GB) 2017-03-09 US disclosed
WO-2015189560-A1 AGENTS FOR USE IN THE TREATMENT OF CARDIOVASCULAR AND INFLAMMATORY DISEASES STRUCTURALLY BASED ON 4(1 H)-QUINOLONE UCL BUSINESS PLC (GB) 2015-12-17 WO disclosed
WO-2015189560-A1 AGENTS FOR USE IN THE TREATMENT OF CARDIOVASCULAR AND INFLAMMATORY DISEASES STRUCTURALLY BASED ON 4(1 H)-QUINOLONE UCL BUSINESS PLC (GB) 2015-12-17 WO disclosed
EP-0841929-B1 QUINOLONES AND THEIR THERAPEUTIC USE DARWIN DISCOVERY LTD (GB) 2003-05-07 EP disclosed
US-5891878-A Quinolones and their therapeutic use CHIROSCIENCE LIMITED (GB) 1999-04-06 US disclosed
US-5262559-A BETA-KETOESTERS WHICH ARE CHEMICAL INTERMEDIATES FOR BACTERICIDES ABBOTT LABORATORIES (US) 1993-11-16 US disclosed
US-4994599-A Antibacterial agents ABBOTT LABORATORIES (US) 1991-02-19 US disclosed
US-RE32975-E FUNGICIDES, BACTERICIDES, FEED ADDITIVES BAYER AKTIENGESELLSCHAFT (DE) 1989-07-04 US disclosed
US-4284629-A ANIMAL GROWTH REGULATORS BAYER AKTIENGESELLSCHAFT (DE) 1981-08-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170066722-A1 AGENTS FOR USE IN THE TREATMENT OF CARDIOVASCULAR AND INFLAMMATORY DISEASES STRUCTURALLY BASED ON 4(1 H)-QUINOLONE CBR3, AGTR1, CBR1 LMNA 565/4885TDP1 3855/4885NR4A2 28/4885
US-10087144-B2 Agents for use in the treatment of cardiovascular and inflammatory diseases structurally based on 4(1 H)-quinolone AGTR1, CBR3, CBR1 LMNA 565/4885TDP1 3610/4885NR4A2 28/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.